1. Home
  2. IPSC vs SLGL Comparison

IPSC vs SLGL Comparison

Compare IPSC & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IPSC
  • SLGL
  • Stock Information
  • Founded
  • IPSC 2019
  • SLGL 1997
  • Country
  • IPSC United States
  • SLGL Israel
  • Employees
  • IPSC N/A
  • SLGL N/A
  • Industry
  • IPSC Medicinal Chemicals and Botanical Products
  • SLGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • IPSC Health Care
  • SLGL Health Care
  • Exchange
  • IPSC Nasdaq
  • SLGL Nasdaq
  • Market Cap
  • IPSC 42.2M
  • SLGL 49.4M
  • IPO Year
  • IPSC 2021
  • SLGL 2018
  • Fundamental
  • Price
  • IPSC $0.49
  • SLGL $22.79
  • Analyst Decision
  • IPSC Strong Buy
  • SLGL
  • Analyst Count
  • IPSC 5
  • SLGL 0
  • Target Price
  • IPSC $3.33
  • SLGL N/A
  • AVG Volume (30 Days)
  • IPSC 698.6K
  • SLGL 30.5K
  • Earning Date
  • IPSC 08-14-2025
  • SLGL 08-15-2025
  • Dividend Yield
  • IPSC N/A
  • SLGL N/A
  • EPS Growth
  • IPSC N/A
  • SLGL N/A
  • EPS
  • IPSC N/A
  • SLGL N/A
  • Revenue
  • IPSC $114,128,000.00
  • SLGL $23,931,000.00
  • Revenue This Year
  • IPSC $1,589.94
  • SLGL N/A
  • Revenue Next Year
  • IPSC N/A
  • SLGL $31.17
  • P/E Ratio
  • IPSC N/A
  • SLGL N/A
  • Revenue Growth
  • IPSC 5491.77
  • SLGL 264.86
  • 52 Week Low
  • IPSC $0.34
  • SLGL $4.01
  • 52 Week High
  • IPSC $1.86
  • SLGL $26.89
  • Technical
  • Relative Strength Index (RSI)
  • IPSC 37.35
  • SLGL 67.74
  • Support Level
  • IPSC $0.46
  • SLGL $21.00
  • Resistance Level
  • IPSC $0.55
  • SLGL $23.91
  • Average True Range (ATR)
  • IPSC 0.04
  • SLGL 2.62
  • MACD
  • IPSC -0.00
  • SLGL 0.27
  • Stochastic Oscillator
  • IPSC 25.00
  • SLGL 66.14

About IPSC Century Therapeutics Inc.

Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.

About SLGL Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.

Share on Social Networks: